- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Bausch + Lomb, Novaliq Receive FDA Approval for Dry Eye Disease Treatment
Miebo reported as the first cleared remedy that directly targets tear evaporation.
Bausch + Lomb, a global eye care company, and Novaliq, a biopharmaceutical company, have officially announced that the FDA has approved Miebo, a treatment for dry eye disease. Reportedly, the medication is the first and only FDA-approved treatment that directly targets tear evaporation.
“Today’s FDA approval of MIEBO further advances dry eye disease treatment by addressing a significant unmet need for millions of people suffering with this disease,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “We are proud to bring to market the first and only prescription eye drop approved in the United States for the treatment of dry eye disease that directly targets evaporation. We expect to make MIEBO commercially available in the second half of this year.”
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
